Non-small cell lung cancer (NSCLC) accounts for the majority of lung cancer cases in Canada [1], with anaplastic lymphoma kinase (ALK)-positive NSCLC occurring in approximately 1–5% of patients with NSCLC [2,3]. This evidence concerns the gene ALK and non-small cell lung carcinoma.